thanks!!...... excerpting......
A number of other companies are taking a variety of additional approaches
to deriving and commercializing stem cell therapies. Some, such as Stem
Cell Sciences (Victoria, Australia), are also developing nuclear transfer and
cell immortalization strategies that will compete with Geron's technologies.
Currently, the company isolates and purifies stem cells from embryonic
tissue using a differentially expressed gene, said Peter Mountford, Ph.D.,
CEO and scientific director. Company-supported scientists have also
discovered a gate-keeper gene, Oct-3/4, that defines differentiation,
dedifferentiation or self-renewal of ESCs (here), and a small molecule
inhibitor of ES cell differentiation. Stem Cells Inc. also plans to leverage its
expertise in nuclear reprogramming. At this time, growing ESCs in vitro is
Stem Cell Inc.'s major challenge, Mountford says. |
